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Abstract 
Background: Hepatitis A is a common infection during childhood, especially in developing countries. It can 
cause severe complications in immunocompromised patients. Due to the increasing number of kidney 
transplants in the country and epidemiologic shift of HAV which was observed in previous studies, we're going 
to evaluate the seroprevalence of hepatitis A in hemodialysis patients less than forty years serving kidney 
transplant candidates to follow vaccination policy for them. 
Materials and Methods: In a cross sectional study during 2014-2015 hepatitis A antibody levels in 
hemodialysis patients less than forty years in kidney transplant candidates examined in 12 hospitals in Tehran, 
Iran. Their serums were tested for anti HAV IgM and IgG by ELISA kits. 
Results: Hepatitis A virus antibody was positive in 66 (72.5%) of 91 patients. The prevalence of HAV was 
0% at the range of younger than 20 and 45% in under 25 years age group. This significantly increased 
prevalence by increasing the age, and there was according to epidemiological shifts which were shown in 
other studies. 
Conclusion: Due to the availability of vaccine and hepatitis severe complications in immunocompromised 
individuals, as well as a low prevalence of positive serology in individuals under 25 years, it seems the check of 
antibodies in patients undergoing kidney transplantation and vaccination in seronegative persons is a logical. 
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Introduction 
One of the most common viral infections for liver is 
hepatitis A which is a RNA virus belonging to the 
Picornaviridae family with a worldwide distribution. 
Pattern of the disease includes infection during early 
childhood followed by life-long immunity
1
. During 
last decades, the age of infection by this virus has 
shifted from early childhood to adolescence or even 
later since to an improvement in sanitation
2,3
. 
Hepatitis A virus (HAV) is mainly transmitted 
through ingestion of contaminated food or water or 
through contact with an infected patient (oral-fecal 




The expression of clinical symptoms depends on and 
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varies with the age of the infected person. While 
children with less than 6 years of age mostly have 
asymptomatic infection hepatitis A is not a clinical 
problem
5
. Thus, vaccination for hepatitis A is 
generally not recommended in communities where 
new infections are mainly limited to children. With 
increasing age, HAV infection leads to a more serious 
disease, older persons usually experience some 
specific symptoms of this illness, e.g., jaundice and 
dark urine lasting for  several weeks, and rarely acute 
liver failure and death
6
. So, in communities where a 
significant percentage of adults have no immunity, the 
increased morbidity that occurs with hepatitis A 
amongst adults might justify vaccination, especially 
when travelling to an endemic area
2
. 
A study in 1980 in Iran, indicated that 95% of the 
blood donors had serologic markers of a previous 
infection with HAV
7
. Routine vaccination against 
hepatitis A is not currently recommended in Iran. 
However the current status is uncertain, especially in 
the general population. During recent decades and in 
parallel to improvement in health care systems among 
developing countries, the pattern of this viral infection 
has shifted from childhood to adolescence with more 
severe and Annual medical and work loss costs of 
hepatitis A are significant even in low-endemic 
countries. Recently, Iran has witnessed a substantial 
improvement in the standard of living and general 
health, even in remote rural areas
8
. As a result, we 
might expect an increase in the percent of adults 
susceptible to HAV
4
. Such an increased susceptibility, 
if of a large enough magnitude, might justify routine 
vaccination of children. 
In haemodialysis patients, data on hepatitis A 
vaccination is limited
9,10
. These patients are known to 




These patients and especially those with underlying 
liver disease like chronic hepatitis B or C should be 
vaccinated against hepatitis A. In the several studies 
vaccination against HAV and HBV is recommended 
for patients with chronic liver disease evaluated for 
liver transplantation if they are not immunized
11,12
. 
The aim of the following study is to investigate the 
current seroprevalence of HAV in hemodialysis 
patient younger than forty years. 
Methods 
A cross sectional observational study was conducted 
from November 2014 to February 2016. Blood was 
collected at blood collection centers of 12 hospitals 
including Moddares, Ashrafi-Esfehani, Shohada, 
Imam-Hossein, Loghman, Taleghani, Labbafi-Nejad, 
Resalat dialysis center, Sorena, Madaen, Shariati and 
Pediatric clinical center from hemodylysis patients 
under forty years old.  
Using a questionnaire, epidemiological data including 
age, gender and level of education were collected. 
With prior written consent, clinical history and 
relevant data were recorded and 2 ml of blood was 
collected from the study cases. Sera were separated, 
stored at -80°C and were tested for HAV antibody 
(IgG and IgM) by ELISA technique using the ELISA 
kit (Dignostic Bioprobes, Italy). The cut-off value 
was determined by the mean absorbance of the 
calibrator values. The presence or absence of anti-
HAV was determined by comparing the absorbance 
values of unknown samples with the absorbance 
values below/ above the cut-off values of the controls. 
A preformed semi structured data collecting form was 
used as a data collection instrument. Data were 
collected by researcher and analyzed by Statistical 
Package for Social Science (SPSS) version18 
program. The p value <0.05 is considered as 
statistically significant. 
Results 
Hepatitis A virus antibody (total) was found positive 
in 66 (72.5%) of 91 haemodialysis patients between 
15-40 years old. There were 66 (72.7%) men and a 
mean age of patients is 21.7. 
Table 1 shows sex-specific distribution of anti-HAV 
antibody among our patients. There was no significant 
relationship between seropositivity and sex (p= 
0.945). According to the level of education, 
participants were categorized as follows: 2.1% of the 
study population were “uneducated;” 31.8% of 
subjects had a “preliminary education;” 36.2% 
completed third year of high school; 5.4 % of subjects 
had high school diploma, 12% had continued their 
education after diploma, 2.1 had continued their 
education in graduate school and 9.8% were 
unanimous. Seroprevalence of anti-HAV antibody 
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according to the level of education is shown in Table 
1. All of uneducated individuals were found anti-
HAV positive. However, there was no statistically 
significant different in anti-HAV seroprevalence 
among participants with different levels of education 
(p = 0.289). 
Age distribution of the patients who were positive for 
HAV antibody shows that with the advancement of 
age, anti-HAV positivity increases. 
Anti-HAV of 15-19.9 years age group was found to 
be 0%, it gradually increased to 45.5% in 20-24.9 
year age group, 80 % in 25-29.9, 75% in 30-34.9% 
and finally to 88.9% in 35-40 year age group. Anti-
HAV positivity of 35-40 year age group was 
significantly higher than other groups (Table 2). 
Discussion 
Acute viral hepatitis caused by HAV is an acute, self-
limiting infection
13
. Hepatitis A virus infection is very 
common in early childhood before the age of five 
with asymptomatic or mild pattern
14
. Immunity that 
develops following natural infection is stronger and 
persists longer than that develops following 
vaccination.  
HAV epidemiological pattern are highly dependent on 
socio-economic conditions, and level of hygiene. The 
seroprevalence distribution of HAV by age group 
may reflect current hepatitis A endemicity in 
countries and regions. Iran is located in the vicinity of 
countries of Middle East and south Asia with high 
endemicity of HAV infection. HAV is highly 
prevalent in the Iranian population. Previous studies 
reported, mostly based on healthy blood donors, a rate 
of 95% or more in adults
7,15
.  
In this cross-sectional study, we investigated the 
seroprevalence of HAV among hemodialysis patient 
younger than forty years in 12 hospitals in Tehran-
Iran. 
Although in the current study, the seroprevalence of 
anti- HAV in male was slightly greater than female 
subjects, the difference was not statistically 
significant. It seems that there is no difference in 
predisposition of both genders to HAV infection in 
the country. 
In the present study the prevalence of HAV at the age 
range of 15-19.9 years was 0%. Anti-HAV 
seroprevalence increased with age from 0% in 15-
19.9 year age group to 45% in the 25-29.9 year age 
group. Similar results were also observed in other 
Table 1: Seroprevalence of anti-HAV antibody according to sex and level of education. 
 Negative No (%) Positive No (%) 
Sex   
   Male 18 (27.3%) 48 (72.7%) 
   Female  7 (28%) 18 (72%) 
Education   
   Uneducated 0 (0%) 2 (100%) 
   Preliminary 5 (17.3%) 24(82.7% )  
   High school 10 (30.3%) 23 (69.7%) 
   Diploma 3 (60%)  2 (40%) 
   Post-diploma 2 (18.2%) 9 (81.8%) 
   Graduate School  1 (50%) 1(50%) 
   Unanimous  4 (45%)  5 (55%) 
 
 Table 2: Anti-HAV positivity with age. 
Age(yrs) N 
(%) 
            HAV antibody  
Positive               Negative 
15-19.9 5 (0)   0                             5 
20-24.9 11(45.5)   5                             6 
25-29.9 20 (80)  16                            4 
30-34.9 28 (75)  21                            7 
35-40 27 (88.9)  24                            3 
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studies in Bangladesh
16
. Ahmed et al,
16
 found a high 
prevalence (74.8%) of anti-HAV among Bangladeshi 
children and adult. He also reported anti-HAV 
positivity of 38% in 1-5 year age group, 75.2% in 5-
10 year age group, 80.4% in 11-15 year age group and 
98.5% in 15-20 year age group. Saha et al,
17
 also 
reported anti-HAV positivity of 40% in 1-5 year age 
group which gradually increased to 98.4% in >30 year 
age group. Another study by Sheikh et al,20 reported 
anti-HAV positivity of 100% in 15-20 year age group. 
Farajzadegan
18
 in a review article in 2014 that 
examines 16 Seroepidemiology hepatitis A systematic 
review achieved the significant results. Seropositive 
prevalence varies in different locations and it was 
between 8-19%. This difference is linked to the health 
and socio-economic level. The prevalence was lower 
in urban areas than rural and there is no difference in 
sex, in addition other studies in Egypt and Saudi 
Arabia and Iraq have also been that way. We studied 
the prevalence of sero-positive residents of 
subetalurbs of Tehran with Tehran residents which 
showed no significant difference (78% vs. 70%). 
We also determined the seroprevalence of HAV in 
seven groups of education. The serprevalence of HAV 
antibody was lower in participants with higher 
educations (Table 1); the rate was 100% in 
uneducated peoples. 
24 kidney transplants per million people annually in 
Iran and Iranian done very successfully in the region 
has had a kidney transplant
19
. It is also one of the 
vaccines Hepatitis A vaccine is recommended in 
organ transplantation
20
. An immune response in 
patients before and after transplantation of a kidney 
transplant to 98% and even 74% in some studies was 
26.9%.  
Negative serological prevalence of 27.5% in 
hemodialysis patients in our study showed that 
responding to transplant patients to hepatitis A can 
Jeon Considering the looks you in his study in 2011, 
31.8%
21
 prevalence of positive serology in patients 
under forty years kidney transplant showed a 26.9% 
response to the vaccine due to screen antibodies in the 
patients in chronic kidney disease and transplantation 
is needed before vaccination
22
. 
Regarding to low endemicity of hepatitis A infection 
in recent years in the Iran, it seems logic that efforts 
should be made to vaccinate high-risk populations 
along with more improvement in environmental 
hygiene and sanitations
18
. Studies from some other 
regions of the world have reported same result as 
decreases in the endemic prevalence of infectious 




Finally, making decisions for controlling HAV and 
providing a national vaccination guideline is a 
complex process which depends on many variables 
such as disease burden, feasibility, cost effectiveness, 
and vaccine efficacy, among others
26
. At the end, this 
study considers Iran one of the countries with low 
endemicity which has recommended vaccination for 
high risk choices. 
Conclusion 
In conclusion, due to the low prevalence of 
seropositive for hepatitis A in patients less than 
twenty years of age in our study was, it seems to set 
policy of the vaccination in routine childhood 
immunizations of the country needs to do a study with 
sufficient sample size and widespread. 
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